Literature DB >> 8410070

Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy.

G Sobue1, M Doyu, T Kachi, T Yasuda, E Mukai, T Kumagai, T Mitsuma.   

Abstract

Four of 8 definite heterozygous female carriers determined by PCR amplification of tandem CAG repeat of the AR gene, from 4 families of X-linked recessive bulbospinal neuronopathy (X-BSNP) showed extensive high amplitude motor unit potentials in examined muscles although all subjects were neurologically normal. Plasma creatine kinase, myoglobin, myosin light chain, lactate and pyruvate were all normal even in the carriers who showed EMG abnormalities. Muscle biopsy showed a type 2 fiber preponderance and possible very mild type 2 fiber grouping in a carrier with an EMG abnormality. These results suggest that a mutant AR gene may express subclinical phenotypic manifestations in a subpopulation of the heterozygous females of X-BSNP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410070     DOI: 10.1016/0022-510x(93)90157-t

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  16 in total

1.  Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy.

Authors:  Atsushi Hashizume; Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Noriaki Suga; Fumiaki Tanaka; Gen Sobue
Journal:  J Neurol       Date:  2011-09-28       Impact factor: 4.849

2.  Highly skewed inactivation of the wild-type X-chromosome in asymptomatic female carriers of spinal and bulbar muscular atrophy (Kennedy's disease).

Authors:  C Paradas; F Solano; F Carrillo; C Fernández; J Bautista; E Pintado; M Lucas
Journal:  J Neurol       Date:  2008-05-02       Impact factor: 4.849

Review 3.  CAG-polyglutamine-repeat mutations: independence from gene context.

Authors:  J M Ordway; J A Cearley; P J Detloff
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 4.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

5.  The androgen receptor's CAG/glutamine tract in mouse models of neurological disease and cancer.

Authors:  Andrew P Lieberman; Diane M Robins
Journal:  J Alzheimers Dis       Date:  2008-06       Impact factor: 4.472

6.  Clinical features of spinal and bulbar muscular atrophy.

Authors:  Lindsay E Rhodes; Brandi K Freeman; Sungyoung Auh; Angela D Kokkinis; Alison La Pean; Cheunju Chen; Tanya J Lehky; Joseph A Shrader; Ellen W Levy; Michael Harris-Love; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Brain       Date:  2009-12       Impact factor: 13.501

7.  CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model.

Authors:  Hiroaki Adachi; Masahiro Waza; Keisuke Tokui; Masahisa Katsuno; Makoto Minamiyama; Fumiaki Tanaka; Manabu Doyu; Gen Sobue
Journal:  J Neurosci       Date:  2007-05-09       Impact factor: 6.167

8.  Decrease in androgen binding and effect of androgen treatment in a case of X-linked bulbospinal neuronopathy.

Authors:  A Danek; T N Witt; K Mann; H U Schweikert; G Romalo; A R La Spada; K H Fischbeck
Journal:  Clin Investig       Date:  1994-11

Review 9.  Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.

Authors:  Masahisa Katsuno; Hiroaki Adachi; Fumiaki Tanaka; Gen Sobue
Journal:  J Mol Med (Berl)       Date:  2004-02-27       Impact factor: 4.599

Review 10.  Polyglutamine androgen receptor-mediated neuromuscular disease.

Authors:  Elisa Giorgetti; Andrew P Lieberman
Journal:  Cell Mol Life Sci       Date:  2016-05-17       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.